NanoVibronix, Inc. Files 2023 Annual Report on Form 10-K

Ticker: FEED · Form: 10-K · Filed: Apr 8, 2024 · CIK: 1326706

Nanovibronix, Inc. 10-K Filing Summary
FieldDetail
CompanyNanovibronix, Inc. (FEED)
Form Type10-K
Filed DateApr 8, 2024
Risk Levellow
Pages15
Reading Time18 min
Key Dollar Amounts$0.001, $1.1 million
Sentimentneutral

Sentiment: neutral

Topics: 10-K, Annual Report, NanoVibronix, Financials, SEC Filing

TL;DR

<b>NanoVibronix, Inc. has filed its 2023 annual report (10-K) detailing its financial performance and business operations.</b>

AI Summary

NanoVibronix, Inc. (FEED) filed a Annual Report (10-K) with the SEC on April 8, 2024. NanoVibronix, Inc. filed its 2023 Form 10-K on April 8, 2024. The filing covers the fiscal year ending December 31, 2023. The company's principal business is in Orthopedic, Prosthetic & Surgical Appliances & Supplies. The company is incorporated in Delaware. The filing includes detailed financial information for the fiscal years 2023, 2022, and 2021.

Why It Matters

For investors and stakeholders tracking NanoVibronix, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of NanoVibronix's financial health and strategic direction for the fiscal year 2023, crucial for investors to assess performance and future prospects. The detailed financial data, including comparisons across multiple fiscal years, allows stakeholders to track trends, evaluate profitability, and understand the company's capital structure.

Risk Assessment

Risk Level: low — NanoVibronix, Inc. shows low risk based on this filing. The filing is a standard annual report (10-K) and does not contain immediate red flags or significant negative developments, indicating a routine disclosure.

Analyst Insight

Investors should review the detailed financial statements and risk factors within the 10-K to understand NanoVibronix's operational performance and market position.

Key Numbers

  • 2023-12-31 — Fiscal Year End (Period covered by the 10-K)
  • 2024-04-08 — Filing Date (Date the 10-K was filed)
  • 2023 — Fiscal Year (Primary year of reporting)
  • 2022 — Prior Fiscal Year (Comparative year)
  • 2021 — Prior Fiscal Year (Comparative year)

Key Players & Entities

  • NanoVibronix, Inc. (company) — Filer name
  • 2023 (date) — Fiscal year end
  • April 8, 2024 (date) — Filing date
  • 3842 (other) — Standard Industrial Classification code
  • DE (other) — State of incorporation
  • NY (other) — State of business address
  • 914-233-3004 (other) — Business phone number

FAQ

When did NanoVibronix, Inc. file this 10-K?

NanoVibronix, Inc. filed this Annual Report (10-K) with the SEC on April 8, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by NanoVibronix, Inc. (FEED).

Where can I read the original 10-K filing from NanoVibronix, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by NanoVibronix, Inc..

What are the key takeaways from NanoVibronix, Inc.'s 10-K?

NanoVibronix, Inc. filed this 10-K on April 8, 2024. Key takeaways: NanoVibronix, Inc. filed its 2023 Form 10-K on April 8, 2024.. The filing covers the fiscal year ending December 31, 2023.. The company's principal business is in Orthopedic, Prosthetic & Surgical Appliances & Supplies..

Is NanoVibronix, Inc. a risky investment based on this filing?

Based on this 10-K, NanoVibronix, Inc. presents a relatively low-risk profile. The filing is a standard annual report (10-K) and does not contain immediate red flags or significant negative developments, indicating a routine disclosure.

What should investors do after reading NanoVibronix, Inc.'s 10-K?

Investors should review the detailed financial statements and risk factors within the 10-K to understand NanoVibronix's operational performance and market position. The overall sentiment from this filing is neutral.

How does NanoVibronix, Inc. compare to its industry peers?

NanoVibronix operates within the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry, a sector focused on medical devices and equipment.

Are there regulatory concerns for NanoVibronix, Inc.?

The company is subject to standard SEC regulations for public companies, including the requirement to file annual reports (10-K) detailing financial performance and business activities.

Industry Context

NanoVibronix operates within the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry, a sector focused on medical devices and equipment.

Regulatory Implications

The company is subject to standard SEC regulations for public companies, including the requirement to file annual reports (10-K) detailing financial performance and business activities.

What Investors Should Do

  1. Review the full 10-K filing for detailed financial statements and management's discussion and analysis.
  2. Analyze the company's operational segments and any disclosed revenue streams.
  3. Assess the risk factors section for potential challenges and uncertainties facing NanoVibronix.

Key Dates

  • 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K.
  • 2024-04-08: Filing Date — Date the 10-K was officially submitted to the SEC.

Year-Over-Year Comparison

This filing is the annual 10-K for fiscal year 2023, providing a comprehensive update compared to previous filings.

Filing Stats: 4,512 words · 18 min read · ~15 pages · Grade level 14.6 · Accepted 2024-04-08 17:30:36

Key Financial Figures

  • $0.001 — ch registered Common stock, par value $0.001 per share NAOV NASDAQ Capital Mark
  • $1.1 million — ees and expenses of up to approximately $1.1 million subject to certain adjustments, includi

Filing Documents

: RISK FACTORS

ITEM 1A: RISK FACTORS 35

: UNRESOLVED STAFF COMMENTS

ITEM 1B: UNRESOLVED STAFF COMMENTS 54

: CYBERSECURITY

ITEM 1C: CYBERSECURITY 54

: PROPERTIES

ITEM 2: PROPERTIES 55

: LEGAL PROCEEDINGS

ITEM 3: LEGAL PROCEEDINGS 55

: MINE SAFETY DISCLOSURES

ITEM 4: MINE SAFETY DISCLOSURES 56 PART II. 57

: MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES

ITEM 5: MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES 57

: [RESERVED]

ITEM 6: [RESERVED] 58

: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 7: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 59

: QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ITEM 7A: QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 66

: FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

ITEM 8: FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 66

: CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

ITEM 9: CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 66

: CONTROLS AND PROCEDURES

ITEM 9A: CONTROLS AND PROCEDURES 67

: OTHER INFORMATION

ITEM 9B: OTHER INFORMATION 68

: Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

ITEM 9C: Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. 68 PART III. 68

: DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE

ITEM 10: DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE 68

: EXECUTIVE COMPENSATION

ITEM 11: EXECUTIVE COMPENSATION 69

: SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

ITEM 12: SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 69

: CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

ITEM 13: CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 69

: PRINCIPAL ACCOUNTANT FEES AND SERVICES

ITEM 14: PRINCIPAL ACCOUNTANT FEES AND SERVICES 69 PART IV.

: EXHIBITS, FINANCIAL STATEMENT SCHEDULES

ITEM 15: EXHIBITS, FINANCIAL STATEMENT SCHEDULES 69

: FORM 10-K SUMMARY

ITEM 16: FORM 10-K SUMMARY 69

SIGNATURES

SIGNATURES 77 PART I ITEM 1. BUSINESS Cautionary Note Regarding Forward-Looking Statements; Risk Factor Summary This Annual Report on Form 10-K contains "forward-looking statements," which include information relating to future events, future financial performance, financial projections, strategies, expectations, competitive environment and regulation. Words such as "may," "should," "could," "would," "predicts," "potential," "continue," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," and similar expressions, as well as statements in future tense, identify forward-looking statements. Forward-looking or results will be achieved. Forward-looking statements are based on information we have when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to a number of risks, and uncertainties and assumptions that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. These risks are more fully described in the "Risk Factors" section of this Annual Report on Form 10-K. The following is a summary of such risks: Our history of losses and expectation of continued losses. Global economic and political instability and conflicts, such as the conflict between Russia and Ukraine, and Israel and certain hostile entities, could adversely affect our business, financial condition or results of operations. Increasing inflation could adversely affect our business, financial condition, results of operations or cash flows. Our ability to raise funding for, and the timing of, clinical studies and eventual U.S. Food and Drug Administration ("FDA") approval of our product candidates. Our product candidates may not be developed or commercialized successfully. R

Business

Business Model All of our products consist of a reusable controller device and a disposable component, which includes a transducer, and in the case of PainShield, a 30-day supply of adhering patches. Th

View Full Filing

View this 10-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.